presentation - novartis
Post on 12-Mar-2016
301 Views
Preview:
DESCRIPTION
TRANSCRIPT
Dr. Stephan Mumenthaler Head Economic and Swiss Public Affairs Istanbul, November 22, 2012
Innovation through Corporate R&D
Leading market position
One of 35 largest companies by market capitalization
Among most respected companies globally
Novartis is a world-leading healthcare company
2011 CHF billion
Net sales: 51.8
Net income: 8.2
R&D investment: 8.5
Key figures
Canada/ Latin America
US
Europe Asia/Africa/ Australasia
Sales by region – 2011
1 CHF = USD 1.13
2 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
We believe our portfolio best meets the varied and often complex needs of patients and societies Environment Patient needs Novartis portfolio
Pharmaceuticals
Vaccines and Diagnostics
Sandoz (Generics)
Full range of healthcare options
Innovative medicines Prevention Affordable options Self-care
Alcon
(Eye care)
Consumer Health (OTC and Animal Health)
3 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Novartis
Pfizer/Wyeth
Merck/SGP
Roche/Genentech
BMS
AstraZeneca
J&J**
Sanofi-Aventis
Eli Lilly
Bayer
GSK
US FDA EU EMA Japan PMDA China SFDA
15
11
10
13
6
3
5
4
5 5
2
8
3
6
5
6
4
3
2
1
3
1
Notes: Does not include vaccines; Novartis includes Alcon and co-developed or co-marketed products from Ciba Vision, QLT, Idenix, Genentech; Pfizer includes products of Pharmacia + Wyeth; Merck includes products of Schering Plough + Organon; Roche includes products of Genentech and Chugai (JP); J&J includes products of Janssen +Centocor+ RWJohnson EU approvals for all companies are inclusive of fixed-dose combinations and confirmed EC decisions Source: FDA, EMA, PMDA, SFDA/CDE databases (as of 31 Jan 2012)
New chemical/molecular entity (NCE/NME) approvals for selected companies 2007 – 2011
By leveraging our R&D capabilities, we are leading the industry in productivity
4
6
3
1
3
3
4
8
3
2
13
3
1
1
3
2
8
10
9
10
12
17
4 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Novartis Pharma and Corporate Research and Development 2012: worldwide community 2012
Emeryville (USA): NIBR
La Jolla (USA): GNF, Genomics Institute
East Hanover (USA): NIBR & Pharma Development
Alcon Forth Worth (USA): Ophtalmology
Cambridge (USA): NIBR, Pharma Development,
Vaccines Research
Horsham (UK): NIBR & Pharma
Development Basel (CH): NIBR, Pharma Development & Friedrich Miescher Institute for
Biomedical Research (FMI)
Siena (IT): Vaccines
NITD Singapore (SG): Tropical Diseases
Shanghai & Changshu (CN): NIBR & Pharma
Development
Hyderabad (IN): Pharma
Development
Tokyo (JP): Pharma
Development
5 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
The most important research center of Novartis is Switzerland
Novartis is continually investing in R&D in Switzerland • In 2011 the R&D investment amounted to 3.3 billion francs • The research programs are supported by cooperative ventures, for
example with the prestigious Paul Scherrer Institute
Basel is not only the global headquarters of Novartis, but also its largest research center • Around 13 550 associates
are employed in Switzerland, over 2 800 of them in research
• Basel’s Friedrich Miescher Institute is also part of the global research network of Novartis
6 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Innovations require attractive framework conditions
• protection of intellectual property • attractive tax system • political und economical stability
enterprise-friendly framework conditions
• uncomplicated raise of capital • beneficial interest rates • promote risk capital for spin-offs
creation of investment incentives
• price differentiation • recoveries • market access
protection and promotion of innovations
• focusing on the needs of leading scientists (e.g. international schools) attracting leading scientists
• allocate educational resources to develop specific areas of competence
• foster natural sciences foster educational
competence
7 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Switzerland is one of the most innovative and competitive economies
Factors considered: Institutions, infrastructure, macro-economic stability, health and elementary school education, university education and training, efficiency of capital goods markets, jobs market efficiency, development of financial markets, technological developments, market size, developent of companies and innovation
Rank 1 Rank 2 Rank 3 Rank 4 Rank 5
Source: EVD (2102)
8 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Switzerland’s strengths
Legal Security 1848 Original form of Swiss constitution
Integration 23% of the population are foreigners
Education 61% of school pupils are in a dual system
Discipline 98% of trains run on time
Industry 83% of 15 to 64- year-olds are in work
Endurance 34 years Rail 2000
9 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
But there are also weaknesses: Switzerland is a very high wage country
Source: BfS (2012)
Labot costs per hour,
in euros
≥ 40.0 30.0 – 39.9 20.0 – 29.9 10.0 – 19.9 < 10.0 No data
10 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Most OECD countries promote R&D with tax incentives – not Switzerland
Direct government funding of business R&D and tax incentives for R&D, 2009, as a percentage of GDP
0.000.050.100.150.200.250.300.350.40
Sw
itzer
land
Finl
and
Ger
man
y
Sw
eden
Sou
th A
frica
Spa
in
Bra
zil
Turk
ey
Nor
way
Uni
ted
Stat
es
Japa
n
Uni
ted
King
dom
Aus
tralia
Aus
tria
Hun
gary
Por
tuga
l
Net
herla
nds
Slo
veni
a
Irela
nd
Bel
gium
Can
ada
Fran
ce
Direct government funding of BERD Indirect government support through R&D tax incentivesSource: OECD SCIENCE, TECHNOLOGY AND INDUSTRY SCOREBOARD 2011
11 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Improving the investment environment and encouraging foreign investment
Increasing production output for export: Increasing exports by an average of 11.2 percent annually at current prices, for USD 185.1 billion by 2014 and USD 500 billion by 2023
Reducing the current account deficit from 9.4% to 7% as a percentage of GDP by 2014
Increasing total R&D Expenditure as a percentage of GNP to 2% by 2013, and to 3% by 2023
Supporting R&D and Innovation: Completing regulatory preparations, promoting establishment of laboratories, and facilitating systems of conformity assessment and market oversight to improve product quality and ensure safety of marketed products, to develop a capacity for producing high added-value products.
TURKEY 3- Year Medium-Term Program and Vision 2023
12 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
Fostering Innovation – Policy Recommendations Attractive framework conditions for
leading class scientific companies which aspire to invest (e.g. IP, tax system)
Provide investment incentives comparable to other countries (e.g. Singapore)
Protect and foster innovation (e.g. differentiated pricing, reimbursement, market access)
Increase attractiveness of location for leading researchers (e.g. international schools, infrastructure)
Build education portfolio with focus on competence fields (foster natural sciences)
13 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012
top related